期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 50, 期 1, 页码 249-260出版社
IOS PRESS
DOI: 10.3233/JAD-150799
关键词
Activity-dependent neuroprotective protein (ADNP); Alzheimer's disease; amyloid-beta; blood-borne biomarkers; cognitively normal; mild cognitive impairment; premorbid intelligence
资金
- AMN Foundation
- Israel Ministry of Science, Technology and Space
- Israel Science Foundation
- CFTAU Montreal Circle of Friends
- Adams family
- Adams Super Center for Brain Studies
- Elton Laboratory for Molecular Neuroendocrinology
- Lily and Avraham Gildor Chair for the Investigation of Growth Factors at Tel Aviv University
- Harvard Aging Brain Study [P01 AGO36694, R01 AG037497]
- Massachusetts Alzheimer's Disease Research Center [P50 AG005134]
- Harvard NeuroDiscovery Center Biomarker Study (HBS)
Biomarkers for Alzheimer's disease (AD) are vital for disease detection in the clinical setting. Discovered in our laboratory, activity-dependent neuroprotective protein (ADNP) is essential for brain formation and linked to cognitive functions. Here, we revealed that blood borne expression of ADNP and its paralog ADNP2 is correlated with premorbid intelligence, AD pathology, and clinical stage. Age adjustment showed significant associations between: 1) higher premorbid intelligence and greater serum ADNP, and 2) greater cortical amyloid and lower ADNP and ADNP2 mRNAs. Significant increases in ADNP mRNA levels were observed in patients ranging from mild cognitive impairment (MCI) to AD dementia. ADNP2 transcripts showed high correlation with ADNP transcripts, especially in AD dementia lymphocytes. ADNP plasma/serum and lymphocyte mRNA levels discriminated well between cognitively normal elderly, MCI, and AD dementia participants. Measuring ADNP blood-borne levels could bring us a step closer to effectively screening and tracking AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据